Our trustees and non-execs

Andy is the Global Practice Head – Real Estate at Linklaters. He has been at Linklaters for over 25 years and has extensive experience in the acquisition, financing, development, letting and disposal of all types of commercial real estate both in the UK and Continental Europe. Andy is listed as a Leading Individual in The Legal 500 and ranked in Chambers. He is Trustee and Chair of Barts Charity.

Ian is Co-Chair of UK Investment Banking at UBS. He was recently seconded for three years to the Takeover Panel as its Director General. He is a qualified chartered accountant and has previously worked at Citigroup and Morgan Stanley.

Lorna is a haematologist specialising in Transfusion Medicine. After 20 years as an academic clinician in Cambridge, she became national Medical and Research Director of NHS Blood and Transplant. She has held many national and international advisory roles on transfusion safety and research, and has recently been Clinical Director for Communications to the Royal College of Pathologists. She is currently a Non-Executive Board member of the Human Tissue Authority and a Fellow Commoner of Lucy Cavendish College, Cambridge.

Sally is Director of Unquoted Investments at Caledonia Investments plc and formerly Head of Healthcare Investment teams at private equity investors, Permira and PPM Capital (now Silverfleet). Her non-executive directorships include Gala Bingo, Choice Care Group and the Sloane Club.

Catherine is Full Professor of Molecular Medicine at University College Dublin (UCD) where she heads up the Diabetes Complications Research Centre at the Conway Institute. She is on the board of the Health Research Board Ireland, the European Medical Research Council and the Physiological Sciences Committee of the Wellcome Trust, and has served as Vice President, Innovation UCD.

Adam is acting chair of Barts Health NHS Trust and by virtue of holding that post also becomes a trustee of Barts Charity. He was a senior civil servant for many years and worked at the Treasury and the Department for Work and Pensions.

Jean is CEO at Recognise Bank. She has spent her career in wealth management roles at a number of city firms such as Goldman Sachs, ACPI Investments Ltd and Morgan Stanley and led her own wealth advisory business providing investment consultancy and management services. She is also a member of the Investment Committee of Jesus College Cambridge.

Nimesh is CEO at Spirax Sarco Engineering plc, a FTSE100 company. He was formerly CFO of the De Beers Group and Group Head of Corporate Finance at Anglo American plc. He has also spent 14 years in investment banking at both JP Morgan and as a Managing Director at UBS.

Richard is an independent health strategy consultant and a former partner and health leader at Ernst & Young LLP. He is a Visiting Senior Fellow at the Nuffield Trust and has formerly worked at the King’s Fund and Cabinet Office.

Thomas is a GP at the Bromley by Bow Health Partnership. He is also an Academic Clinical Research Fellow in Primary Care and Public Health Sciences at King’s College London. He is Clinical Lead for the Royal College of General Practitioners (RCGP) Essential Knowledge Updates programme and a member of the National Cancer Research Institute primary care clinical studies group. He also represents the Royal College of GPs on the management board of the National Institute for Health and Care Excellence Collaborating Centre for Cancer.

Steve was a Partner and former Head of Healthcare at Bridgepoint Development Capital, a mid market private equity fund manager and part of the FTSE listed Bridgepoint Group, where he spent 15 years. He has 25 years of finance and investing experience, focused on investing in growth companies in private markets across the UK and Europe. He qualified as a Chartered Accountant and is a CFA charterholder.

Dr Kanchan Rege Thrasher is Associate Medical Director of the North West Anglia NHS Foundation Trust, having previously held the role of Executive Director. While in the Chief Medical Officer role, her focus areas have been medical education, research and development, health inequalities, Emergency Planning, Medico-legal services, and Equality, Diversity and Inclusion. She is also Chair of East of England Medical Directors’ Forum and remains a practicing Consultant Haematologist.

Professor Mirela Delibegovic is Dean for Industrial Engagement in Research and Knowledge Transfer and Chair at the Institute of Medical Sciences University of Aberdeen. As a pharmacologist, Professor Delibegovic focuses on how ageing and poor nutrition lead to development of diseases such as diabetes, cardiovascular disease, cancer and other age-associated co-morbidities. She is also Chair of the Diabetes UK RD Lawrence Fellowship and Grants Committees, on the Advisory Board of the Diabetes Research & Wellness Foundation and Vice-Chair of British Heart Foundation Project Grants Committee.

Mohammad is a chartered accountant with more than 20 years of experience in professional services. He is COO and Executive Director at Europe Arab Bank (EAB) plc, part of the Arab Bank Group, one of the largest Middle Eastern financial institutions. Formerly he worked at KPMG and Ernst & Young.

Philip has worked in the investment management industry for over thirty years. Most recently he was Chief Investment Officer of HSBC Global Asset Management (UK) Ltd where he headed all of their London-based investment management activities. Prior to that he spent thirteen years as an investment consultant and asset manager at Russell Investments, where he was Global Head of Manager Research.

Pro Vice-Chancellor for Student Experience, at the University of Bristol where she previously held the role of Head of Medical School and Associate Dean. A practicing GP. Professor Purdy was former Director of NIHR CLAHRC West and is an active non-Executive Director of the North Bristol NHS Trust. She was awarded an OBE in 2022’s Queen’s Birthday Honours.

Dr McDermott is Chief Scientist at AstraZeneca with a focus on drug resistance in cancer, functional genomics and understanding how cancer genomes affect response to therapy. Formally at the Wellcome Sanger Institute as a clinician scientist, he remains a practicing Consultant Oncologist, with a focus on colorectal cancer at Addenbrooke’s Hospital, Cambridge.